ERBB2 and breast carcinoma: Moreover, T-DXd received FDA approval in HER2-low breast cancer based on the results of the DESTINY-Breast 04 trial, which was a phase III clinical trial involving patients with HER2-low metastatic breast cancer who had already received two lines of prior chemotherapy [14].